TYGACIL

PeakSM

tigecycline

NDAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2005
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

Pharmacologic Class:

Tetracycline-class Antibacterial

Clinical Trials (5)

NCT01789905N/ACompleted

Tygacil Drug Use Investigation

Started Apr 2013
116 enrolled
Intra-Abdominal InfectionsSkin Disease, Infectious
NCT01721408Phase 4Completed

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

Started Nov 2012
470 enrolled
Intra-abdominal Infection
NCT01560143Phase 4Completed

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

Started Mar 2012
12 enrolled
Obesity
NCT00911573Phase 3Withdrawn

Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

Started Aug 2011
0
Skin DiseasesInfection
NCT01401023N/ACompleted

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

Started Jul 2011
10 enrolled
DiarrheaClostridium Difficile

Loss of Exclusivity

LOE Date
Oct 8, 2030
55 months away
Patent Expiry
Oct 8, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
10588975
Mar 13, 2026
Product
9254328
Mar 13, 2026
Product
9694078
Mar 13, 2026
Product
8975242
Oct 24, 2028
Product
7879828
Feb 5, 2029
Product